公开(公告)号：US20250042976A1

公开(公告)日：2025-02-06

申请号：US18704654

申请日：2022-10-25

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Simon Jochum ,  Ute Jucknischke ,  Ulrike Kurtkaya ,  Michael Schraeml ,  Sandrine Carolina Stiegler

IPC: C07K16/10

Abstract: The present invention relates to monoclonal antibodies binding to the Receptor Binding Domain of the Spike protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, method of detecting SARS-CoV-2 virus in a sample comprising using said antibodies and methods of using said antibodies in immunoassays.

公开(公告)号：US20230406909A1

公开(公告)日：2023-12-21

申请号：US18251393

申请日：2021-10-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Ute Jucknischke ,  Ulrike Kurtkaya ,  Thomas Mock ,  Michael Schraeml ,  Sandrine Carolina Stiegler

IPC: C07K16/10

CPC classification number: C07K16/1003 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.

公开(公告)号：US20240400672A1

公开(公告)日：2024-12-05

申请号：US18662694

申请日：2024-05-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Gerg ,  Klaus Hirzel ,  Caroline Dorothea Hojer ,  Hans-Peter Josel ,  Ute Jucknischke ,  Holger Lehmann ,  Anastasia Markina ,  Giuseppe Prencipe ,  Leopold von Proff ,  Michael Schraeml ,  Steinar Halldórsson

IPC: C07K16/26 ,  G01N33/78

Abstract: The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93; Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.

公开(公告)号：US20240140995A1

公开(公告)日：2024-05-02

申请号：US18542054

申请日：2023-12-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Romina Eisenhauer ,  Alfred Engel ,  Ute Jucknischke ,  Michael Schraeml ,  Wojtek Steffen

IPC: C07K14/195 ,  G01N33/543

CPC classification number: C07K14/195 ,  G01N33/54353 ,  C07K2319/00 ,  G01N2333/245

Abstract: The present invention relates to a method of determining an analyte in a sample, said method comprising (a) contacting said sample with (i) a binding compound binding to said analyte, said binding compound comprising a binding agent and a first partner of an affinity pair (first affinity partner); and (ii) a second partner of the affinity pair (second affinity partner) coupled to a solid surface, to an indicator, and/or to a second binding agent; and (b) determining said analyte based on complexes formed in step (a); wherein one of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a sequence at least 50% identical thereto, and wherein the other of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a sequence at least 50% identical thereto. The present invention also relates to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:1 or a sequence at least 50% identical thereto, wherein the amino acid at the position corresponding to position 77 in SEQ ID NO:1 is not a histidine; and to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:2 or a sequence at least 50% identical thereto, wherein (i) the amino acid at the position corresponding to position 17 in SEQ ID NO:2 is not a cysteine, in an embodiment is alanine, serine, leucine, isoleucine, or glycine and/or (ii) said polypeptide further comprises at least one functional peptide; and to fusion polypeptides, polypeptide complexes, polynucleotides and kit related to the aforesaid.

公开(公告)号：US20230095167A1

公开(公告)日：2023-03-30

申请号：US17801469

申请日：2021-02-19

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht ,  Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Michael Gerg ,  Ute Jucknischke ,  Johann Karl ,  Peter Kastner ,  Thomas Meier ,  Lars Hillringhaus ,  Ulrich Schotten ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler ,  Roberto Latini ,  Jennifer Marie Theresia Anna Meessen

IPC: G01N33/74 ,  G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.